Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 10th 2015

Genetic Variation Could Prompt Hearing Loss in Young Cancer Patients on Cisplatin

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations associated with rapid hearing loss in young cancer patients treated with the drug cisplatin, as published in Nature Genetics.

February 10th 2015

Takeda's Ixazomib Improves PFS in Multiple Myeloma, Interim Analysis Finds

Interim analysis during a phase 3 study of Ixazomib in patients with relapsed or refractory multiple myeloma found that the drug improved the primary endpoint of progression-free survival.

February 9th 2015

Velcade Approved for Mantle Cell Lymphoma in Europe

The drug has been approved for treatment-naive patients who are ineligible for transplant.

February 6th 2015

FDA Approval for 3D Breast Imaging System Developed by an Academic Startup

The 3D breast imaging system, developed at the University of Rochester, is currently approved for diagnosing cancer in women who have signs or symptoms of the disease, or who have abnormal findings after a standard screening mammogram.

February 6th 2015

CMS Adds Medicare Coverage for LDCT Screening for Lung Cancer in Certain Patients

Mary K. Caffrey

Following an announcement that Medicare would cover preventive low dose computes tomography for lung cancer screening, CMS released a final national coverage determination today that includes details on eligibility criteria.

February 5th 2015

Study Results Support Early Treatment With Abiraterone in Prostate Cancer

Surabhi Dangi-Garimella, PhD

A study published in the journal Lancet Oncology, conducted by the Institute of Cancer Research (ICR), London, provides evidence for the value of introducing abiraterone prior to chemotherapy in these patients.

February 5th 2015

Strategic Oncology Partnership Between AstraZeneca and MD Anderson

The industry-academic partnership is expected to boost clinical trials on investigational drugs and outcomes research, in gynecological cancers.

February 5th 2015

Pfizer to Buy Injectables Giant Hospira

With several of it's blockbusters going off-patent soon, Pfizer is looking at new avenues for expanding it's revenue.

February 5th 2015

FDA Commissioner Hamburg Stepping Down

After nearly 6 years overseeing public health initiatives, Margaret Hamburg, MD, commissioner of the FDA will be stepping down, according to various sources.

February 4th 2015

Smoking Increases Risk of Mortality in CRC Survivors

A comprehensive study published in the Journal of Clinical Oncology found that colorectal cancer survivors who smoke cigarettes were at more than twice the risk of death than non-smoking survivors.

February 4th 2015

Evidence-Based Care Can Eliminate Gaps in Cancer Survival Rates

Laura Joszt, MA

Although African Americans have had lower colon cancer survival rates over the past 2 decades compared with white patients, researchers at the Stanford University School of Medicine have found evidence-based care can remove the racial disparity.

February 4th 2015

FDA Announces Measure to Ease Patient Access to Investigational Drugs

In his blog post on FDAVoice, Peter Lurie MD, MPH, associate FDA commissioner for public health strategy and analysis, announced the introduction of a draft form and a draft guideline that can be used by a physician to request access to an experimental drug or biological product that is still under development.

February 4th 2015

IOM Report Addresses Responsible Sharing of Clinical Trial Data

The report, according to ASCO, delineates responsibilities of different stakeholders towards ensuring responsible data sharing of trial results.

February 3rd 2015

Palbociclib Approved for Post-Menopausal Women With Advanced Breast Cancer

The efficacy of the CDK4/6 inhibitor was demonstrated in 165 postmenopausal women with ER-positive, HER2-negative advanced breast cancer who had not received previous treatment for advanced disease.

February 3rd 2015

Study Compares Adjuvant Radiotherapy With Observation in Low-Risk DCIS

The study, published in the Journal of Clinical Oncology concluded that the failure rate was low with observation but was decreased significantly with the addition of radiotherapy.

February 3rd 2015

"Methylome" Could Distinguish Aggressive Triple-Negative Breast Cancer

The study identified distinct methylation patterns between the aggressive and benign forms of TNBC, which could provide an improved understanding of disease outcome.

February 3rd 2015

Cost-Effectiveness Decisions: Who Do You Trust?

A study published in the Journal of Thoracic Disease digs deep into understanding the assumptions in HEOR studies that evaluate the cost-effectiveness of personalized cancer treatments.

February 3rd 2015

Panel Discussion: The Road to Personalized Medicine: Clinical Utility and Reimbursement in Molecular Diagnostics

Panelists discuss ways to improve the focus on clinical utility in molecular diagnostics given challenges in the system and needs of patients.

February 2nd 2015

Study Substantiates Cost-Effectiveness of Biomarker-Based NSCLC Treatment

Multiplexed genetic screening for EGFR and ALK gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic NSCLC setting in the United States, researchers report in The Journal of Thoracic Oncology.

February 2nd 2015

Genentech's Anti-PD-L1 Agent Receives Breakthrough Status in Advanced NSCLC

With 3 I-O agents have already been approved for metastatic melanoma, 2 from BMS and 1 from Merck, the race for NSCLC has tightened with multiple ongoing clinical trials.

January 30th 2015

Dendreon Sees Light at the End of the Provenge Tunnel

The Canadian company Valeant Pharmaceuticals International Inc has reached an agreement to buy the prostate cancer immunotherapy from Dendreon Corp.

January 30th 2015

Precision Oncology Clinical Service Partnership Announced

The integrated cancer services offered by Sarah Cannon will soon be supported by the personalized medicine technology platform of Syapse, to improve individualized patient care, the companies have announced.

January 30th 2015

Dr Howard K. Kaufman on the Need for More Diverse Populations in Clinical Trials

Clinical trials are critical for pushing the oncology field forward, but there is a need for not only more patients to participate in clinical trials, but for a more diverse population, said Howard K. Kaufman, MD, FACS.

January 29th 2015

The Role of mHealth in Oncology

Mobile health (mHealth) can be so much more than smartphone apps, and it is a growing movement in the United States that can empower patients, providers, and payers, according to Meg Maley, RN, BSN, founder and CEO of CanSurround.

January 29th 2015

Imbruvica Approved for Waldenstrom's Macroglobulinemia

The drug, jointly developed by Pharmacyclics and Janssen Biotech, has received prior approvals for 3 other indications.

January 29th 2015

Smoking Promotes Disease Progression in Prostate Cancer, Study Reports

Smokers diagnosed with prostate cancer who were treated with radiation were at a greater risk of their cancer returning, metastasizing, and ultimately causing death. Former smokers, however, did not have the increased risk.

January 29th 2015

Eli Lilly Expects Multiple Stakeholders Will Benefit from CII, a PACE Initiative

PACE has launched an evidence-based online tool, Continuous Online Indicators, which will provide information on research progress in 12 tumor types.

January 28th 2015

Segment 11: Two Paradigms Being Presented in Medical Oncology

Daniel F. Hayes, MD, outlines the 2 paradigms presented in medical oncology: one where people would rather be overtreated rather than miss a chance to benefit by being undertreated and another where a person might not be willing to do something until they learn there is a reason to do so.

January 28th 2015

Segment 10: The Important Distinction Between Diagnostic, Screening Tests

There is an important distinction between diagnostic and screening tests, and they have different issues in regards to decision making-although the person making treatment decisions should ultimately be guiding the ship, according to Bryan Loy, MD, MBA.

January 28th 2015

Segment 9: Who Should Order the Test?

Both Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, agree that the role of genetic counselors should be limited when order diagnostic tests in medical oncology.

...

141 142 143 144 145 146 147 148 149

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions